Xenon Pharmaceuticals (XENE) Receivables - Net (2013 - 2025)

Xenon Pharmaceuticals (XENE) has 13 years of Receivables - Net data on file, last reported at $8.6 million in Q1 2025.

• On a quarterly basis, Receivables - Net rose 938.3% year-over-year to $8.6 million in Q1 2025; TTM through Mar 2025 was $8.6 million, a 938.3% increase from a year earlier, with the FY2024 full-year figure at $1.5 million, up 68.08% from the prior year.
• Receivables - Net for Q1 2025 stood at $8.6 million, up from $1.5 million in the prior quarter.
• Over the last five years, Receivables - Net for XENE reached as high as $8.6 million in Q1 2025 and fell as low as $805000.0 in Q3 2023.
• Historically, Receivables - Net has averaged $2.5 million across 5 years, with a median of $2.2 million in 2023.
• Across the five-year window, Receivables - Net slumped 67.57% in 2023 and jumped 938.3% in 2025, its largest moves.
• Year by year, Receivables - Net stood at $2.8 million in 2021, then slumped by 64.34% to $986000.0 in 2022, then decreased by 11.36% to $874000.0 in 2023, then surged by 68.08% to $1.5 million in 2024, then jumped by 488.77% to $8.6 million in 2025.
• Per Business Quant data, the three most recent Receivables - Net figures were $8.6 million in Q1 2025, $1.5 million in Q4 2024, and $938000.0 in Q3 2024.